A detailed history of D. E. Shaw & Co., Inc. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 290,396 shares of ALXO stock, worth $490,769. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290,396
Holding current value
$490,769
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.81 - $8.13 $491,335 - $2.21 Million
271,456 Added 1433.24%
290,396 $528,000
Q2 2024

Aug 14, 2024

BUY
$5.84 - $17.56 $110,609 - $332,586
18,940 New
18,940 $114,000
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $21,625 - $69,148
4,496 Added 9.84%
50,178 $747,000
Q3 2023

Nov 14, 2023

SELL
$4.19 - $7.35 $10,579 - $18,558
-2,525 Reduced 5.24%
45,682 $219,000
Q2 2023

Aug 14, 2023

BUY
$4.37 - $9.56 $31,166 - $68,181
7,132 Added 17.36%
48,207 $362,000
Q1 2023

May 15, 2023

BUY
$4.52 - $11.71 $68,487 - $177,429
15,152 Added 58.45%
41,075 $185,000
Q4 2022

Feb 14, 2023

BUY
$9.51 - $12.95 $6,657 - $9,065
700 Added 2.78%
25,923 $292,000
Q3 2022

Nov 14, 2022

SELL
$8.23 - $15.14 $75,411 - $138,727
-9,163 Reduced 26.65%
25,223 $241,000
Q2 2022

Aug 15, 2022

BUY
$5.89 - $19.46 $202,533 - $669,151
34,386 New
34,386 $278,000
Q4 2021

Feb 14, 2022

SELL
$21.49 - $74.4 $165,687 - $573,624
-7,710 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$52.51 - $80.91 $2 Million - $3.08 Million
-38,109 Reduced 83.17%
7,710 $569,000
Q2 2021

Aug 16, 2021

SELL
$52.2 - $75.23 $336,115 - $484,405
-6,439 Reduced 12.32%
45,819 $2.51 Million
Q1 2021

May 17, 2021

BUY
$62.84 - $87.68 $2.85 Million - $3.98 Million
45,423 Added 664.56%
52,258 $3.85 Million
Q4 2020

Feb 16, 2021

BUY
$34.11 - $112.26 $233,141 - $767,297
6,835 New
6,835 $589,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $68.9M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.